Identification of Critical Pathways and Potential Key Genes in Poorly Differentiated Pancreatic Adenocarcinoma

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501. doi:10.1038/nature14169
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.can-14-0155
   PubMed Web of Science ®Google Scholar
• Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12(6):319–334. doi:10.1038/nrclinonc.2015.53
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85. doi:10.1016/S0140-6736(16)00141-0
   PubMed Web of Science ®Google Scholar
• Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271(5247):350–353. doi:10.1126/science.271.5247.350
   PubMed Web of Science ®Google Scholar
• Shang M, Zhang L, Chen X, Zheng S. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis. Discov Med. 2019;28(153):159–172.
   PubMed Web of Science ®Google Scholar
• Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer. Cancers (Basel). 2017;9:5. doi:10.3390/cancers9050042
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Masugi Y, Effendi K, et al. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. Lab Invest. 2014;94(6):683–691. doi:10.1038/labinvest.2014.53
   PubMed Web of Science ®Google Scholar
• Zheng B, Peng J, Mollayup A, et al. Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes. Mol Med Rep. 2018;17(1):216–224. doi:10.3892/mmr.2017.7850
   PubMed Web of Science ®Google Scholar
• Xu JZ, Wang WQ, Zhang WH, et al. The loss of SMAD4/DPC4 expression associated with a strongly activated hedgehog signaling pathway predicts poor prognosis in resected pancreatic cancer. J Cancer. 2019;10(17):4123–4131. doi:10.7150/jca.30883
   PubMed Web of Science ®Google Scholar
• Huijberts S, van Geel R, van Brummelen EMJ, et al. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemother Pharmacol. 2020;85(5):917–930. doi:10.1007/s00280-020-04066-4
   PubMed Web of Science ®Google Scholar
• Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153–168. doi:10.1038/s41575-019-0245-4
   PubMed Web of Science ®Google Scholar
• Hallajzadeh J, Maleki Dana P, Mobini M, et al. Targeting of oncogenic signaling pathways by berberine for treatment of colorectal cancer. Med Oncol. 2020;37(6):49. doi:10.1007/s12032-020-01367-9
   PubMed Web of Science ®Google Scholar
• Moore A, Donahue T. Pancreatic cancer. JAMA. 2019;322(14):1426. doi:10.1001/jama.2019.14699
   PubMedGoogle Scholar
• Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9(2):67–81. doi:10.1006/scbi.1998.0119
   PubMed Web of Science ®Google Scholar
• Kelleher M, Singh R, O’Driscoll CM, Melgar S. Carcinoembryonic antigen (CEACAM) family members and inflammatory bowel disease. Cytokine Growth Factor Rev. 2019;47:21–31. doi:10.1016/j.cytogfr.2019.05.008
   PubMed Web of Science ®Google Scholar
• Beauchemin N, Draber P, Dveksler G, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res. 1999;252(2):243–249. doi:10.1006/excr.1999.4610
   PubMed Web of Science ®Google Scholar
• Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res. 2005;65(19):8809–8817. doi:10.1158/0008-5472.can-05-0420
   PubMed Web of Science ®Google Scholar
• Sato K, Mori R, Hiroshima Y, et al. RT-PCR of peritoneal washings predicts peritoneal pancreatic cancer recurrence. J Surg Res. 2018;226:122–130. doi:10.1016/j.jss.2017.11.009
   PubMed Web of Science ®Google Scholar
• Johnson B, Mahadevan D. Emerging role and targeting of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in human malignancies. Clin Cancer Drugs. 2015;2(2):100–111. doi:10.2174/2212697x02666150602215823
   PubMedGoogle Scholar
• Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40(5):403–439. doi:10.1046/j.1365-2559.2002.01387.x
   PubMed Web of Science ®Google Scholar
• Depianto D, Kerns ML, Dlugosz AA, Coulombe PA. Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nat Genet. 2010;42(10):910–914. doi:10.1038/ng.665
   PubMed Web of Science ®Google Scholar
• Chen PJ, Hsu JD, Han CP. Anti-cytokeratin CAM 5.2 is specific for K8 and to a lesser extent for the closely related K7, but shows no reactivity with K18 or K19: comment on: “keratin expression in endocrine organs and their neoplasms” Endocr Pathol. 2009 Spring; 20(1):1–10. Endocr Pathol. 2010;21(1):69–70. doi:10.1007/s12022-010-9108-9
   PubMed Web of Science ®Google Scholar
• Masuda N, Murakami K, Kita Y, et al. Trp53 mutation in Krt5-expressing basal cells facilitates the development of basal squamous-like invasive bladder cancer in the chemical carcinogenesis of mouse bladder. Am J Pathol. 2020;190(8):1752–1762. doi:10.1016/j.ajpath.2020.04.005
   PubMed Web of Science ®Google Scholar
• Chen W, Zhang W, Wu R, Cai Y, Xue X, Cheng J. Identification of biomarkers associated with histological grade and prognosis of gastric cancer by co-expression network analysis. Oncol Lett. 2019;18(5):5499–5507. doi:10.3892/ol.2019.10869
   PubMed Web of Science ®Google Scholar
• Yang B, Zhang W, Zhang M, Wang X, Peng S, Zhang R. KRT6A promotes EMT and cancer stem cell transformation in lung adenocarcinoma. Technol Cancer Res Treat. 2020;19:1533033820921248. doi:10.1177/1533033820921248
   Web of Science ®Google Scholar
• Grimm SL, Bu W, Longley MA, Roop DR, Li Y, Rosen JM. Keratin 6 is not essential for mammary gland development. Breast Cancer Res. 2006;8(3):R29. doi:10.1186/bcr1504
   PubMed Web of Science ®Google Scholar
• Slusser-Nore A, Garrett SH, Zhou XD, Sens DA, Sens MA, Somji S. The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells. Toxicol Appl Pharmacol. 2017;331:41–53. doi:10.1016/j.taap.2017.05.007
   PubMed Web of Science ®Google Scholar
• Hu J, Zhang LC, Song X, Lu JR, Jin Z. KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro. Int J Clin Exp Pathol. 2015;8(8):9182–9188.
   PubMed Web of Science ®Google Scholar
• Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31(1):11–24. doi:10.1016/0092-8674(82)90400-7
   PubMed Web of Science ®Google Scholar
• Pujal J, Huch M, Jose A, et al. Keratin 7 promoter selectively targets transgene expression to normal and neoplastic pancreatic ductal cells in vitro and in vivo. FASEB J. 2009;23(5):1366–1375. doi:10.1096/fj.08-115576
   PubMed Web of Science ®Google Scholar
• Regitnig P, Spuller E, Denk H. Insulinoma of the pancreas with insular-ductular differentiation in its liver metastasis–indication of a common stem-cell origin of the exocrine and endocrine components. Virchows Arch. 2001;438(6):624–628. doi:10.1007/s004280100406
   PubMed Web of Science ®Google Scholar
• Bournet B, Pointreau A, Souque A, et al. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Pancreatology. 2012;12(1):27–34. doi:10.1016/j.pan.2011.12.003
   PubMed Web of Science ®Google Scholar
• Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer. 1999;85(1):171–177. doi:10.1002/(SICI)1097-0142(19990101)85:1<171::AID-CNCR24>3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem. 1998;31:205–262.
   PubMedGoogle Scholar
• Cheng L, Zhao Y, Tang M, Luo Z, Wang X. Knockdown of ISOC1 suppresses cell proliferation in pancreatic cancer in vitro. Oncol Lett. 2019;17(5):4263–4270. doi:10.3892/ol.2019.10082
   PubMed Web of Science ®Google Scholar
• Goldstein NS, Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol. 2001;115(5):695–702. doi:10.1309/1ncm-46qx-3b5t-7xhr
   PubMed Web of Science ®Google Scholar
• Liu Z, Yu S, Ye S, et al. Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma. J Proteomics. 2020;211:103557. doi:10.1016/j.jprot.2019.103557
   PubMed Web of Science ®Google Scholar
• Chen P, Shen Z, Fang X, et al. Silencing of keratin 17 by lentivirus-mediated short hairpin RNA inhibits the proliferation of PANC-1 human pancreatic cancer cells. Oncol Lett. 2020;19(5):3531–3541. doi:10.3892/ol.2020.11469
   PubMed Web of Science ®Google Scholar
• Roa-Pena L, Leiton CV, Babu S, et al. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Sci Rep. 2019;9(1):11239. doi:10.1038/s41598-019-47519-4
   PubMedGoogle Scholar